title: Pandemic influenza A(H1N1) 2009 vaccines in the European Union.
abstract: Pandemic vaccines from four manufacturers are now available for use within the European Union (EU). Use of these vaccines will protect individuals and reduce the impact on health services to more manageable levels. The majority of the severely ill will be from known risk groups and the best strategy will be to start vaccinating in line with the recommendation from the European Union Health Security Committee prioritizing adults and children with chronic conditions, pregnant women and healthcare workers. The composition of authorized vaccines is reviewed in this article. The vaccine strain in all authorized pandemic vaccines worldwide is based on the same initial isolate of influenza A/California/7/2009 (H1N1)v but the vaccines differ in conditions for virus propagation, antigen preparation, antigen content and whether they are adjuvanted or not. The vaccines are likely to be effective since no significant genetic or antigenic drift has occurred and there are already mechanisms for estimating clinical effectiveness. Influenza vaccines have good safety records and no safety concerns have so far been encountered with any of the vaccines developed. However, special mechanisms have been devised for the early detection and rigorous investigation of possible significant side effects in Europe through post-marketing surveillance and analysis. Delivery of the vaccines to the risk groups will pose difficulties where those with chronic illnesses are not readily identifiable to the healthcare services. There is considerable scope for European added value through Member States with excess vaccines making them available to other states.
authors.affiliation: European Centre for Disease Prevention and Control, Stockholm, Sweden. Kari.Johansen@ecdc.europa.eu
authors.forename: K
authors.initials: K
authors.lastname: Johansen
authors.forename: A
authors.initials: A
authors.lastname: Nicoll
authors.forename: B C
authors.initials: BC
authors.lastname: Ciancio
authors.forename: P
authors.initials: P
authors.lastname: Kramarz
mesh_terms: D005062:European Union; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology; D007251:Influenza, Human / Q000517:prevention & control*; D012306:Risk
chemical_list: D007252:Influenza Vaccines